Syneos Health, Inc. recruits volunteers to help identify coronavirus infections around the world.

k
Employees providing frontline support
Syneos Health, Inc. a global biopharmaceutical solutions organization, is answering the UK Government’s appeal for volunteers to support Covid-19 testing.
The company is enabling clinically-qualified employees to volunteer to perform throat and nasal swabs at the testing stations being established throughout the UK. The program is being led by Syneos Health, Inc. Chief Executive Officer, Alistair Macdonald and supported by the Association of Clinical Research Organizations (ACRO) – the Washington, DC-based body that represents the leading players in the industry.
Syneos Health, Inc. has extended the volunteer program internationally, enabling medical professionals in countries around the globe to participate in Covid-19 support efforts. The company’s 24,000 employees, including doctors, nurses, infectious disease experts, lab technicians and other professionals with frontline healthcare expertise who can provide expertise at this time.
The volunteer program follows Syneos Health, Inc’s. Ventilator Initiative, a public-service program designed to spread awareness of the invasive use of Bi-level Positive Airway Pressure (BiPAP) devices. These can be used as a bridging measure to treat patients on an emergency basis, helping to address the predicted shortage of mechanical ventilators.
Already available in many hospitals, BiPAP machines can delay or remove the need for mechanical ventilation. To educate frontline healthcare providers about their use, the company has mobilized clinical and commercial leaders from across the organization – including specialists in infectious diseases, respiratory medicine, critical care, medical education and training. Information for healthcare professionals is available at http://www.COVID-BipapInfo.com.
Headquartered in North Carolina, USA, Syneos Health, Inc. is the only fully integrated biopharmaceutical solutions organization. It supports customers in more than 110 countries – sharing insights, using the latest technologies, and applying advanced business practices to expedite its customers’ delivery of important therapies to patients.

Back